Bristol Myers director adds deferred share units
Bristol Myers Squibb director Michael R. McMullen reported an acquisition of 3,996.367 Deferred Share Units on February 1, 2026 at $55.05 per unit.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Bristol Myers Squibb director Michael R. McMullen reported an acquisition of 3,996.367 Deferred Share Units on February 1, 2026 at $55.05 per unit. Following this transaction, he beneficially owns 14,979.689 Deferred Share Units directly.
Each Deferred Share Unit will convert into one share of common stock upon settlement, which occurs when McMullen ceases to be a director or at a future date he previously specified. The reported holdings include deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Deferred Share Units | 3,996.367 | $55.05 | $220K |
Footnotes (2)
- F1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
- F2. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did BMY director Michael R. McMullen report?
AI-generated analysis. How Rhea-AI works. Not financial advice.